ImmunoGen Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This ImmunoGen Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP adds recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 21 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply the field and should not be read as evidence of absence.
Executive BD thesis
ImmunoGen presents a practical BD-screening case because its returned pipeline contains 54 records and the deal search returned 21 transaction records. The lead returned asset is Mirvetuximab soravtansine, associated with FOLR1 x Tubulin and Folate receptor-alpha positive, platinumresistant epithelial ovarian cancer, Folate receptor-alpha positive, platinumresistant fallopian tube cancer, Folate receptor-alpha positive, platinumresistant primary peritoneal cancer, at Approved. The immediate objective is not to price a transaction; it is to identify where a focused outreach can unlock regional development, indication expansion, platform access, combination strategy, manufacturing leverage or non-dilutive capital.
The scan prioritizes assets with a named development owner and a traceable stage, then applies a conservative IP screen. A high-quality first meeting should ask for the current clinical/regulatory package, ownership chain, third-party licenses, patent-family schedule, CMC readiness and the specific rights the company is prepared to discuss.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | Mirvetuximab soravtansine | ImmunoGen, Inc. | Approved | Pipeline record: FOLR1 x Tubulin; Folate receptor-alpha positive, platinumresistant epithelial ovarian cancer, Folate receptor-alpha positive, platinumresistant fallopian tube cancer, Folate receptor-alpha positive, platinumresistant primary peritoneal cancer. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | AbbVie wraps up its $10.1B buyout of ImmunoGen well ahead of schedule | Approved asset with FOLR1 x Tubulin exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 2 | Coltuximab ravtansine | ImmunoGen, Inc. | Phase 2 | Pipeline record: CD19 x Tubulin; Acute Lymphoblastic Leukemia, Aggressive Non-Hodgkin Lymphoma. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan | Phase 2 asset with CD19 x Tubulin exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 3 | Eramkafusp alfa | ImmunoGen, Inc. | Phase 1 | Pipeline record: CD20 x Type I IFN Receptor; Non-Hodgkin Lymphoma. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | ImmunoGen has entered into a global, multi-target license and option agreement with Vertex Pharmaceuticals, granting Vertex rights to conduct research using ImmunoGen's ADC technology for the discovery of targeted conditioning agents for us | Phase 1 asset with CD20 x Type I IFN Receptor exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 4 | Laprituximab | ImmunoGen, Inc. | Clinical | Pipeline record: EGFR; Solid tumor. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | AbbVie wraps up its $10.1B buyout of ImmunoGen well ahead of schedule | Clinical asset with EGFR exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 5 | Mirvetuximab | ImmunoGen, Inc. | Clinical | Pipeline record: FOLR1; Neoplasms. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan | Clinical asset with FOLR1 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
Shortlist interpretation. The top row should receive the fastest outreach, subject to confirmation that the returned owner and development stage remain current. Rows two through five are option-value workstreams: they can support a regional license, co-development, research collaboration, asset carve-out or structured option if the evidence package is sufficiently differentiated.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage. Those fields should be reconciled against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, safety narratives, manufacturing comparability and the latest investigator or regulator feedback.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across sources. A mismatch is itself a BD signal: it may reflect a recent transfer, dormant program, territory split, combination strategy or portfolio reprioritization. Any mismatch should be resolved before valuation or term-sheet design.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2023-11-30 | AbbVie wraps up its $10.1B buyout of ImmunoGen well ahead of schedule | Completed | total_amount: 10100; disclosed: false |
| 2023-08-28 | ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan | Active | upfront_payment: 34; disclosed: true |
| 2023-03-01 | ImmunoGen has entered into a global, multi-target license and option agreement with Vertex Pharmaceuticals, granting Vertex rights to conduct research using ImmunoGen's ADC technology for the discovery of targeted conditioning agents for us | Active | upfront_payment: 15; milestone_payment: 337; disclosed: true |
The most relevant returned precedent is: AbbVie wraps up its $10.1B buyout of ImmunoGen well ahead of schedule (2023-11-30). Precedents should guide structure rather than mechanically determine price. Normalize for development stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones and change-of-control provisions. Where economics are undisclosed, the precedent still informs counterparties, strategic intent and preferred transaction form.
Financial capacity and partnering pressure
- ImmunoGen, Inc. - 2023 Quarterly report: ImmunoGen, Inc. - 2023 Quarterly report At March 31, 2023, the Company had $201.2 million of cash and cash equivalents on hand. In April 2023, the Company executed a loan agreement with BioPharma Credit PLC, BPCR Limited Partnership, and BioPharma Credit Investments V (Master) LP, which are funds managed by Pharmakon Advisors, LP (collectively, “Pharmakon”), that provides for up to a $175.0 million senior secured term loan consisting of two tranches that each mature on April 6, 2028. The initial tranche of $75.0 million was drawn upon execution of the loan agreement. The second tranche of $50.0 million will be available at the Company’s option upon the achievement of positive top-line data from the Company’s confirmatory MIRASOL trial and a net sales threshold for ELAHERE. This tranche may
- ImmunoGen, Inc. - 2022 Quarterly report: ImmunoGen, Inc. - 2022 Quarterly report RESULTS OF OPERATIONS We require cash to fund our operating expenses, including the advancement of our clinical programs and to make capital expenditures. Historically, we have funded our cash requirements primarily through equity and convertible debt financings in private and public markets and payments from our collaborators, including license fees, milestone payments, research funding, and royalties. We have also monetized our rights to receive royalties on KADCYLA for upfront consideration. As of September 30, 2022, we had $309.5 million in cash and cash equivalents. Net cash used for operations was $169.6 million and $123.5 million for the nine months ended September 30, 2022 and 2021, respectively. The principal use of cash for operating activi
Financial signals influence timing and leverage. Cash runway, operating burn, committed trial spend, debt covenants, shelf capacity and recent financings determine whether ImmunoGen is more likely to pursue a broad license, regional partnership, cost-sharing collaboration, royalty financing or asset-level option. Figures returned from filings should be rechecked in the latest report before any negotiation.
Recent events and outreach timing
- No company-specific recent-news passage was returned. Confirm the latest clinical, regulatory, financing and leadership events directly with management.
Recent clinical, regulatory, financing, leadership and portfolio events can create a narrow outreach window. The BD team should map each event to a decision owner, an asset-level question and a proposed structure. Avoid generic “partnership interest” messages; lead with the specific program, territory, capability gap and evidence package that the prospective partner can improve.
IP and diligence risk screen
The default IP flag is medium until verified. Review composition-of-matter and sequence claims, method-of-use coverage, formulation and delivery patents, manufacturing know-how, platform licenses, university or government rights, prosecution status, patent-term adjustment/extension, oppositions, litigation, inventorship and freedom to operate. For biologics, cell/gene therapies and platform technologies, background IP and improvement-right provisions can be as important as the asset patents.
Commercial diligence should test addressable population, diagnosis and referral pathway, standard of care, competitor readouts, endpoint sensitivity, payer evidence needs, launch infrastructure and territory-specific regulatory requirements. The value of an asset is a function of the complete evidence package and executable rights—not development stage alone.
Recommended outreach sequence
- Contact the asset-level BD owner with a one-page rationale linked to the lead program and proposed territory or capability contribution.
- Request a non-confidential package covering current stage, dataset maturity, ownership, patent schedule, CMC status and partnering perimeter.
- Benchmark the returned precedents using stage-, modality- and territory-adjusted structures.
- Advance only programs with a coherent owner, evidence package, IP path and decision timeline into confidential diligence.
- Set explicit stop/go gates for data quality, freedom to operate, financing capacity and strategic fit.
Bottom line
ImmunoGen merits targeted BD outreach where the returned pipeline and evidence package align with a partner’s geography, development capability or commercial infrastructure. The recommended next action is to validate Mirvetuximab soravtansine, confirm rights availability and test a structure calibrated to the company’s financial position and precedent set. The shortlist is designed to turn fragmented intelligence into an actionable owner-by-owner outreach plan.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
